When was Agios Pharmaceuticals founded?

Agios Pharmaceuticals was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Agios Pharmaceuticals located?

Agios Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Rīga, Latgales iela 429 - 78.

How many employees does Agios Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at Agios Pharmaceuticals is 675.

Is Agios Pharmaceuticals a funded company?

Agios Pharmaceuticals is a funded company, having raised a total of $120M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 07, 2008.

When was the latest funding round of Agios Pharmaceuticals?

Agios Pharmaceuticals' latest funding was a $***** Post IPO round on Oct 06, 2017, with participation from 0 investor.

What is the annual revenue of Agios Pharmaceuticals?

Annual revenue of Agios Pharmaceuticals is between $50M and $100M as on Dec 31, 2025

Where does Agios Pharmaceuticals rank among its competitors?

Agios Pharmaceuticals ranks 9th amongst 577 active competitors, of which 189 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Agios Pharmaceuticals?

Agios Pharmaceuticals' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Agios Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule, and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK deficiency.

Website: www.agios.com/
Registered Address: Rīga, Latgales iela 429 - 78

Key Metrics

Founded Year

2008

Location

Cambridge, United States

Stage

Public

Total Funding

$120M in 6 rounds

Latest Funding Round

Post IPO, Oct 06, 2017, $*****

Investors

Arch Venture Partners & 7 more

Ranked

9^th among 577 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

675 as on Aug 31, 2026

Similar Companies

BridgeBio & 701 more

Exit Details

Public

View Agios Pharmaceuticals' full profile

Agios Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AGIOS CIN: 40003610059 , Latvia, Active	Nov 20, 2002	€0 - €1M (As on Dec 31, 2024)	1 (As on Dec 31, 2022)	-
Agios Pharmaceuticals Inc CIN: 1439222 , United States, Active	Aug 06, 2007	$50M - $100M (As on Dec 31, 2025)	-	-
AGIOS PHARMACEUTICALS, INC CIN: 26-0662915 , United States, Active	Dec 31, 2007	-	383 (As on Dec 31, 2023)	-

Agios Pharmaceuticals got listed on Jul 24, 2013.

Click here to take a look at Agios Pharmaceuticals's IPO in detail

Agios Pharmaceuticals has raised a total funding of $120M over 6 rounds. Its first funding round was on Jul 07, 2008. Agios Pharmaceuticals has 8 institutional investors.

Here is the list of recent funding rounds of Agios Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 06, 2017	9024019	Post IPO	1778332	9300411	2383835	4603799
Sep 20, 2016	3009483	Post IPO	3777750	9257346	3139572	9979371
Nov 17, 2011	4171505	Series C	7504737	6702966	Celgene & 3 more	9031602

Access funding benchmarks and valuations. Sign up today!

View details of Agios Pharmaceuticals's funding rounds and investors

Agios Pharmaceuticals' employee count trend

Agios Pharmaceuticals has 675 employees as of Aug 26. Here is Agios Pharmaceuticals's employee count trend over the years:

Employee count trend for Agios Pharmaceuticals

Uncover Agios Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Agios Pharmaceuticals include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Agios Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
8th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
9th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	BB Biotech, Sagard & 6 others	70/100
10th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100